How Denosumab works

Denosumab (Denosumab) is a new type of fully human IgG2 monoclonal antibody that is specific for receptor activator of nuclear factor kappa B ligand (RANKL) and inhibits bone resorption by inhibiting RANK-mediated osteoclast activation. Designed to targetRANKL (RANK ligand), a protein that serves as a primary signal that promotes bone removal/resorption. In many cases of bone loss, RANKL disrupts the body's natural defenses against bone destruction. Desosumab prevents RANKL from activating the receptor RANK on the surface of osteoclasts and their precursors. Preventing RANKL/RANK interaction inhibits osteoclast formation, function, and survival, thereby reducing bone resorption and increasing bone mass and strength of cortical and trabecular bone.